The U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel) for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results